Myriad Genetics (MYGN +3.8%) gains on an upgrade to Outperform at Leerink Swann, saying believes...

|About: Myriad Genetics, Inc. (MYGN)|By:, SA News Editor

Myriad Genetics (MYGN +3.8%) gains on an upgrade to Outperform at Leerink Swann, saying believes concerns over the company's reimbursement risk and intellectual property are overdone and that the drug developers product lines are continuing to grow. The firm also raised its price target range to $30 - $31 from $27 - $30.